Verrica Pharmaceuticals Inc.
VRCA
$0.4891
$0.02264.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.57M | 9.21M | 13.91M | 8.91M | 5.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.57M | 9.21M | 13.91M | 8.91M | 5.12M |
| Cost of Revenue | 22.85M | 30.95M | 30.78M | 32.78M | 29.51M |
| Gross Profit | -15.28M | -21.74M | -16.88M | -23.87M | -24.38M |
| SG&A Expenses | 58.82M | 65.94M | 69.91M | 59.33M | 47.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.40M | 84.32M | 92.23M | 83.64M | 68.35M |
| Operating Income | -65.84M | -75.11M | -78.32M | -74.73M | -63.22M |
| Income Before Tax | -76.58M | -84.99M | -86.93M | -80.74M | -67.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -76.58 | -84.99 | -86.93 | -80.74 | -67.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.58M | -84.99M | -86.93M | -80.74M | -67.00M |
| EBIT | -65.84M | -75.11M | -78.32M | -74.73M | -63.22M |
| EBITDA | -64.88M | -74.19M | -77.52M | -74.05M | -62.67M |
| EPS Basic | -1.54 | -1.83 | -1.88 | -1.75 | -1.46 |
| Normalized Basic EPS | -0.96 | -1.11 | -1.14 | -1.06 | -0.88 |
| EPS Diluted | -1.54 | -1.83 | -1.88 | -1.75 | -1.46 |
| Normalized Diluted EPS | -0.96 | -1.11 | -1.14 | -1.06 | -0.88 |
| Average Basic Shares Outstanding | 207.12M | 186.10M | 185.37M | 184.79M | 181.33M |
| Average Diluted Shares Outstanding | 207.12M | 186.10M | 185.37M | 184.79M | 181.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |